Sterile Inflammation after Intravitreal Injection of Aflibercept in a Korean Population
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To report the frequency and clinical features of sterile inflammation after intravitreal aflibercept injection in a Korean population. Methods: A single-center, retrospective study was performed in patients who received intravitreal aflibercept from July 2013 through January 2015. Results: A total of four cases of post-injection sterile inflammation were identified from 723 aflibercept injections in 233 patients. Patients presented 1 to 13 days after intravitreal aflibercept injection (mean, 5 days). The mean baseline visual acuity was 20 / 60, which decreased to 20 / 112 at diagnosis but ultimately recovered to 20 / 60. Three cases had inflammatory cells in the anterior chamber (mean, 2.25+; range, 0 to 4+), and all cases had vitritis (mean, 3+; range, 2+ to 4+). No patients had pain. Only one patient underwent anterior chamber sampling (culture negative) and injection of antibiotics. Three of four patients were treated with a topical steroid, and all experienced improvement in their symptoms and signs of inflammation. Conclusions: The overall incidence of sterile inflammation after intravitreal aflibercept injection in a Korean population was 4 of 723 injections (0.55%), or 4 of 233 patients (1.79%). Sterile inflammation after intravitreal aflibercept injection typically presents without pain, and the visual outcomes are generally favorable.
Abstract
Purpose: To report the frequency and clinical features of sterile inflammation after intravitreal aflibercept injection in a Korean population. Methods: A single-center, retrospective study was performed in patients who received intravitreal aflibercept from July 2013 through January 2015. Results: A total of four cases of post-injection sterile inflammation were identified from 723 aflibercept injections in 233 patients. Patients presented 1 to 13 days after intravitreal aflibercept injection (mean, 5 days). The mean baseline visual acuity was 20 / 60, which decreased to 20 / 112 at diagnosis but ultimately recovered to 20 / 60. Three cases had inflammatory cells in the anterior chamber (mean, 2.25+; range, 0 to 4+), and all cases had vitritis (mean, 3+; range, 2+ to 4+). No patients had pain. Only one patient underwent anterior chamber sampling (culture negative) and injection of antibiotics. Three of four patients were treated with a topical steroid, and all experienced improvement in their symptoms and signs of inflammation. Conclusions: The overall incidence of sterile inflammation after intravitreal aflibercept injection in a Korean population was 4 of 723 injections (0.55%), or 4 of 233 patients (1.79%). Sterile inflammation after intravitreal aflibercept injection typically presents without pain, and the visual outcomes are generally favorable.
참고문헌 (24)
- Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Brown DM, "Ranibizumab for macular edema following central retinal vein occlusion:six-month primary end point results of a phase III study", Ophthalmology, 117, pp.1124~1133 (2010)
- Campochiaro PA, "Ranibizumab for macular edema following branch retinal vein occlusion:six-month primary end point results of a phase III study", Ophthalmology, 117, pp.1102~1112 (2010)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- Heier JS, "Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial", Ophthalmology, 119, pp.802~809 (2012)
- Brown DM, "Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials:RISE and RIDE", Ophthalmology, 120, pp.2013~2022 (2013)
- Schmidt-Erfurth U, "Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study", Ophthalmology, 121, pp.1045~1053 (2014)
- Heier JS, "Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration", Ophthalmology, 119, pp.2537~2548 (2012)
- Korobelnik JF, "Intravitreal aflibercept for diabetic macular edema", Ophthalmology, 121, pp.2247~2254 (2014)
- Korobelnik JF, "Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO Study", Ophthalmology, 121, pp.202~208 (2014)
- Schmidt-Erfurth U, "Intravitreal af libercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies", Ophthalmology, 121, pp.193~201 (2014)
- Campochiaro PA, "Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study", Ophthalmology, 122, pp.538~544 (2015)
- Hahn P, "Aflibercept-related sterile inflammation", Ophthalmology, 120, pp.1100~1101 (2013)
- Fine HF, "Frequency and characteristics of intraocular inflammation after aflibercept injection", Retina, 35, pp.681~686 (2015)
- Goldberg RA, "Noninfectious inflammation after intravitreal injection of aflibercept:clinical characteristics and visual outcomes", Am J Ophthalmol, 158, pp.733~737 (2014)
- Bakri SJ, "Intraocular inflammation following intravitreal injection of bevacizumab", Graefes Arch Clin Exp Ophthalmol, 246, pp.779~781 (2008)
- Fauser S, "Intraocular inflammation after intravitreal ranibizumab injections", Acta Ophthalmol, 89, pp.98~99 (2011)
- Kay CN, "Uveitis following intravitreal bevacizumab: a non-infectious cluster", Ophthalmic Surg Lasers Imaging, 42, pp.292~296 (2011)
- Wickremasinghe SS, "Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration", Ophthalmology, 115, pp.1911~1915 (2008)
- Wu L, "Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)", Graefes Arch Clin Exp Ophthalmol, 246, pp.81~87 (2008)
- Georgopoulos M, "Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)", Br J Ophthalmol, 93, pp.457~462 (2009)
- Antoszyk AN, "Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results", Am J Ophthalmol, 145, pp.862~874 (2008)
- Marticorena J, "Sterile endophthalmitis after intravitreal injections", Mediators Inflamm, 2012, pp.928123~ (2012)